

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOOVCATB (Induction)

(Page 1 of 2)

DOCTOR'S ORDERS Htcm Wtkg BS	SAm²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form		
DATE: To be given: Cycle #:		
Date of Previous Cycle:		
□ Delay treatment week(s)□ CBC & Diff, Platelets day of treatment		
May proceed with doses as written if within 72 hours ANC greater than or equal to 1.0 x 10 ⁹ /L, Platelets greater than or equal to 100 x 10 ⁹ /L, BP less than or equal to 150/100, and urine dipstick for protein negative or 1+.		
Dose modification for:		
Proceed with treatment based on blood work from		
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm		
45 minutes prior to PACLitaxel:		
dexamethasone 20 mg IV in 50 mL NS over 15 minutes		
30 minutes prior to PACLitaxel:		
diphenhydrAMINE 50 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible) ondansetron 8 mg PO 30 minutes prior to CARBOplatin. ☐ Other:		
Have Hypersensitivity Reaction Tray and Protocol Available		
CHEMOTHERAPY: (Note – continued over 2 pages)		
☐ CYCLE # 1		
PACLitaxel 175 mg/m² OR mg/m² (select one) x BSA = mg		
☐ Dose Modification:% =mg/m² x BSA =mg		
IV in 250 to 500 mL (non-DEHP bag) NS over 3 hours. (Use non-DEHP tubing with 0.2 micron in-line filter)		
CARBOplatin AUC 6 or 5 (select one) x (GFR + 25) = mg		
☐ Dose Modification:% = mg		
IV in 100 to 250mL NS over 30 minutes.		
ORDERS CONTINUE ON PAGE 2		
DOCTOR'S SIGNATURE:	SIGNATURE:	
	uc:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GOOVCATB (Induction)

(Page 2 of 2)

DATE:		
<u>OR</u> □ CYCLE # (cycle 2-6)		
PACLitaxel ☐ 175 mg/m² OR ☐ mg/m² (select one) x BSA = mg ☐ Dose Modification: % = mg/m² x BSA = mg IV in 250 to 500 mL (non-DEHP bag) NS over 3 hours. (Use non-DEHP tubing with 0.2 micron in-line filter)		
CARBOplatin AUC ☐ 6 or ☐ 5 (select one) x (GFR + 25) = mg ☐ Dose Modification: % = mg IV in 100 to 250 mL NS over 30 minutes.		
Blood pressure measurement pre-bevacizumab dose.		
bevacizumab 7.5 mg/kg x kg = mg IV in 100 mL NS over 15 minutes (first infusion over 1 hour). (Blood pressure measurement post-bevacizumab infusion for first 3 cycles) Pharmacy to select bevacizumab brand as per Provincial Systemic Therapy Policy III-190		
Drug Brand (Pharmacist to complete. Please print.) Pharmacist Initial and Da	te	
bevacizumab		
RETURN APPOINTMENT ORDERS		
Return in three weeks for Doctor and Cycle		
Last Treatment. Return in week(s).		
CBC & Diff, Platelets, Creatinine, Laboratory urinalysis or Urine dipstick for protein prior to next cycle.		
If this is Cycle 1: CBC & Diff, Platelets on Day 14. In subsequent cycles, if indicated: CBC & Diff, Platelets on Day 14		
☐ 24 h urine for total protein within 3 days prior to next bevacizumab dose if 2+ or 3+ dipstick or greater than or equal to 1 g/L laboratory urinalysis for protein ☐ INR weekly ☐ INR prior to next cycle		
Prior to next cycle, if clinically indicated: Bilirubin Alk Phos GGT ALT LDH Tot Prot Albumin CA 15-3 CA 125 CA 19-9		
☐ Refer to Hereditary Cancer Program (see accompanying referral form)		
☐ Consults:		
See general orders sheet for additional requests.	01001471177	
DOCTOR'S SIGNATURE:	SIGNATURE:	
	UC:	